Vaccination with <i>Plasmodium vivax</i> Duffy-binding protein inhibits parasite growth during controlled human malaria infection-Reference-Cited by-同舟云学术

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection

Published:2023-07-12 Issue:704 Volume:15 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Hou Mimi M.¹²³^ORCID,Barrett Jordan R.¹²³^ORCID,Themistocleous Yrene²^ORCID,Rawlinson Thomas A.²,Diouf Ababacar⁴,Martinez Francisco J.⁵^ORCID,Nielsen Carolyn M.¹²³^ORCID,Lias Amelia M.¹²³^ORCID,King Lloyd D. W.¹²³,Edwards Nick J.²^ORCID,Greenwood Nicola M.²,Kingham Lucy²,Poulton Ian D.²^ORCID,Khozoee Baktash²^ORCID,Goh Cyndi²^ORCID,Hodgson Susanne H.¹²³^ORCID,Mac Lochlainn Dylan J.¹²³^ORCID,Salkeld Jo¹²³^ORCID,Guillotte-Blisnick Micheline⁵,Huon Christèle⁵^ORCID,Mohring Franziska⁶,Reimer Jenny M.⁷^ORCID,Chauhan Virander S.⁸,Mukherjee Paushali⁹^ORCID,Biswas Sumi²,Taylor Iona J.²^ORCID,Lawrie Alison M.²,Cho Jee-Sun¹²³,Nugent Fay L.²^ORCID,Long Carole A.⁴^ORCID,Moon Robert W.⁶^ORCID,Miura Kazutoyo⁴^ORCID,Silk Sarah E.¹²³^ORCID,Chitnis Chetan E.⁵^ORCID,Minassian Angela M.¹²³¹⁰^ORCID,Draper Simon J.¹²³¹⁰^ORCID

Affiliation:

1. Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.

2. Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.

3. Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.

4. Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.

5. Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.

6. Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.

7. Novavax AB, Kungsgatan 109, SE-753 18 Uppsala, Sweden.

8. International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.

9. Multi Vaccines Development Program (MVDP), New Delhi, India.

10. NIHR Oxford Biomedical Research Centre, Oxford, UK.

Abstract

There are no licensed vaccines against Plasmodium vivax . We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% ( n = 6) compared with unvaccinated controls ( n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Link

https://www.science.org/doi/pdf/10.1126/scitranslmed.adf1782

Reference37 articles.

1. World Health Organization “World Malaria Report ” (2021).

2. Plasmodium vivax in the Era of the Shrinking P. falciparum Map

3. Malaria Vaccines: Recent Advances and New Horizons

4. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion.

5. The Resistance Factor to Plasmodium vivax in Blacks

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Precision of thePlasmodium knowlesiGrowth Inhibition Assay forPlasmodium vivaxDuffy-Binding Protein-based Malaria Vaccine Development;2024-01-24

2. Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens;Frontiers in Immunology;2024-01-17

3. PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial;npj Vaccines;2024-01-06

4. Sterile protection againstP. vivaxmalaria by repeated blood stage infection in theAotusmonkey model;Life Science Alliance;2023-12-29

5. Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein;Malaria Journal;2023-12-04